Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
14 Results for "
p38α Mitogen-Activated Protein Kinase
" in MedChemExpress (MCE) Product Catalog:
Products (14)
14 Results for "p38α Mitogen-Activated Protein Kinase" in MCE Product Catalog:
2
2 Cited Publications
Cat. No.: HY-18758
CAS No.: 868612-83-3
Target:
Research Areas:
IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC50 of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC50=36 nM) and p38α mitogen-activated protein kinase (IC50=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .
1
1 Cited Publications
Cat. No.: HY-14974
CAS No.: 449811-92-1
Target:
Research Areas:
R 1487 is an orally active and highly selective p38α mitogen-activated protein kinase inhibitor. R 1487 can be used in the study of rheumatoid arthritis .
1
1 Cited Publications
Cat. No.: HY-P80776A
Synonyms: p38 (phospho T180 + Y182); p-p38 (phospho T180 + Y182); p38 (phospho T180/Y182); CSAID Binding Protein 1; CSAID binding Protein; CSAID-binding Protein; Csaids binding Protein; CSBP 1; CSBP 2; CSBP; CSBP1; CSBP2; CSPB 1; CSPB1; Cytokine suppressive anti inflammatory drug binding Protein; Cytokine suppressive anti-inflammatory drug-binding Protein; EXIP; MAP Kinase 14; MAP Kinase MXI2; MAP Kinase p38 alpha; MAPK 14; MAPK14; MAX interacting Protein 2; MAX-interacting Protein 2; Mitogen Activated Protein Kinase 14; Mitogen Activated Protein Kinase p38 alpha; Mitogen-Activated Protein Kinase 14; Mitogen-Activated Protein Kinase p38 alpha; MK14_HUMAN; Mxi 2; Mxi2; p38 ALPHA; p38; p38 MAP Kinase; p38 MAPK; p38 Mitogen Activated Protein Kinase; p38ALPHA; p38alpha Exip; PRKM14; PRKM15; RK; SAPK 2A; SAPK2A; Stress Activated Protein Kinase 2A.
Synonyms: ATI-450; CDD-450
Target:
Research Areas:
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .
Cat. No.: HY-W015445
CAS No.: 1670-87-7
Target:
Research Areas:
SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation .
Synonyms: (R)-ATI-450; (R)-CDD-450
Target:
Research Areas:
(R)-Zunsemetinib is the isomer of Zunsemetinib (HY-139553), and can be used as an experimental control. Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
p38α inhibitor 1 (Arry-797) is a p38α inhibitor. p38α inhibitor 1 is applicable to research related to diseases including Alzheimer's disease and inflammatory dilated cardiomyopathy .
Cat. No.: HY-161293
CAS No.: 29368-40-9
p38-α MAPK-IN-6 (compound 3a) is a p38α mitogen-activated protein kinase inhibitor .
Cat. No.: HY-175432
CAS No.: 180869-17-4
Target:
Research Areas:
p38 MAPK-IN-9 (Compound 15) is an orally active and highly selective p38α mitogen-activated protein kinase (p38 MAPK) inhibitor with an IC50 value of 9.6 nM. p38 MAPK-IN-9 is promising for research of inflammatory diseases such as rheumatoid arthritis, septic shock, and chronic obstructive pulmonary disease (COPD) .
Cat. No.: HY-18758R
CAS No.: 868612-83-3
Target:
Research Areas:
IN-1130 (Standard) is the analytical standard of IN-1130. This product is intended for research and analytical applications. IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC50 of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC50=36 nM) and p38α mitogen-activated protein kinase (IC50=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .
Cat. No.: HY-P85712
Synonyms: Mitogen-Activated Protein Kinase 14; MAP Kinase 14; MAPK 14; Cytokine suppressive anti-inflammatory drug-binding Protein; CSAID-binding Protein; CSBP; MAP Kinase MXI2; MAX-interacting Protein 2; Mitogen-Activated Protein Kinase p38 alpha; MAP Kinase p38 alpha; Stress-Activated Protein Kinase 2a; SAPK2a;
Cat. No.: HY-P86460
Synonyms: Mitogen-Activated Protein Kinase 14; MAP Kinase 14; MAPK 14; Cytokine suppressive anti-inflammatory drug-binding Protein; CSAID-binding Protein; CSBP; MAP Kinase MXI2; MAX-interacting Protein 2; Mitogen-Activated Protein Kinase p38 alpha; MAP Kinase p38 alpha; Stress-Activated Protein Kinase 2a; SAPK2a;
Cat. No.: HY-W015445R
CAS No.: 1670-87-7
Target:
Research Areas:
SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation .
Cat. No.: HY-119138
CAS No.: 321344-32-5
Target:
Research Areas:
R-130823 is an orally active, highly selective p38α inhibitor with an IC50 of 22 nM against p38α, an IC50 of 820 nM against p38β, and no activity against p38γ or p38δ. R-130823 downregulates downstream cartilage degradation and inflammatory mediators, and inhibits the release of MMP-13, MMP-1 and PGE2. R-130823 reduces hind paw swelling, improves hyperalgesia, and blocks arthritis progression. R-130823 is applicable to research related to osteoarthritis and rheumatoid arthritis .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
